{Reference Type}: Journal Article
{Title}: The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
{Author}: Bancroft EK;Page EC;Brook MN;Pope J;Thomas S;Myhill K;Helfand BT;Talaty P;Ong KR;Douglas E;Cook J;Rosario DJ;Salinas M;Buys SS;Anson J;Davidson R;Longmuir M;Side L;Eccles DM;Tischkowitz M;Taylor A;Cruellas M;Ballestero EP;Cleaver R;Varughese M;Barwell J;LeButt M;Greenhalgh L;Hart R;Azzabi A;Jobson I;Cogley L;Evans DG;Rothwell J;Taylor N;Hogben M;Saya S; ;Eeles RA;Aaronson NK;
{Journal}: BJU Int
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 5
{Factor}: 5.969
{DOI}: 10.1111/bju.16432
{Abstract}: <B>OBJECTIVE: </B>To report the long-term outcomes from a longitudinal psychosocial study that forms part of the 'Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls' (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2).<BR><B>METHODS: </B>Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge.<BR><B>RESULTS: </B>A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time.<BR><B>CONCLUSIONS: </B>This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.